Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Carcinomatous meningitis

verfasst von: Marc C. Chamberlain, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Meningeal carcinomatosis commonly referred to as carcinomatous meningitis (CM), is the third most common central nervous system (CNS) metastatic complication of systemic cancer and is the most morbid of CNS metastases. The disease is challenging to treat for a variety of reasons not least are challenges in making a diagnosis of CM as well as the lack of standardized treatment due to the relative paucity of clinical trials addressing treatment of CM. A diagnosis of CM is achieved by a clinically relevant history and examination, CSF analysis that includes cytology, and neuroimaging consistent with radiographic CM. Treatment following staging of CNS disease (neuraxis imaging and radio-isotope CSF flow study) in appropriate patients (defined as limited extent of disease and reflected in a high performance status) includes systemic chemotherapy for radiographic bulky CSF disease, radiotherapy to sites of symptomatic disease, radiographic bulky disease or sites of CSF flow obstruction, and intra-CSF chemotherapy (primarily methotrexate, cytarabine, or thiotepa). Notwithstanding aggressive treatment, the majority of patients survive < 3 months suggesting patient selection for treatment is critical as is the need for clinical trials utilizing novel therapies.
Literatur
2.
Zurück zum Zitat Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. J Neurooncol. 2012;106(2):225–34.PubMedCrossRef Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. J Neurooncol. 2012;106(2):225–34.PubMedCrossRef
3.
Zurück zum Zitat Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11(9):871–9.PubMedCrossRef Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11(9):871–9.PubMedCrossRef
4.
Zurück zum Zitat Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369–75.PubMedCrossRef Glass JP, Melamed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369–75.PubMedCrossRef
5.
Zurück zum Zitat Gleissner B, Chamberlain MC. Clinical presentation and therapy of neoplastic meningitis. Lancet Neurol. 2006;5:443–52.PubMedCrossRef Gleissner B, Chamberlain MC. Clinical presentation and therapy of neoplastic meningitis. Lancet Neurol. 2006;5:443–52.PubMedCrossRef
6.
Zurück zum Zitat Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neuro Oncol. 1995;23(3):233–8.CrossRef Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neuro Oncol. 1995;23(3):233–8.CrossRef
7.
Zurück zum Zitat Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51–7.PubMedCrossRef Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51–7.PubMedCrossRef
8.
Zurück zum Zitat Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro Oncol. 1998;38(2–3):135–40.CrossRef Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neuro Oncol. 1998;38(2–3):135–40.CrossRef
9.
Zurück zum Zitat Chamberlain MC, Kormanik PA. Prognostic significance of 111-indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674–7.PubMedCrossRef Chamberlain MC, Kormanik PA. Prognostic significance of 111-indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674–7.PubMedCrossRef
10.
Zurück zum Zitat Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54(11):1364–8.PubMedCrossRef Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54(11):1364–8.PubMedCrossRef
11.
Zurück zum Zitat Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–9.PubMedCrossRef Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–9.PubMedCrossRef
12.
Zurück zum Zitat Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1998;50(4):1173–5.PubMedCrossRef Chamberlain MC. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology. 1998;50(4):1173–5.PubMedCrossRef
13.
Zurück zum Zitat Chamberlain MC. Neoplastic meningitis: Deciding who to treat. Expert Rev Neurother. 2004;4(4):89–96.CrossRef Chamberlain MC. Neoplastic meningitis: Deciding who to treat. Expert Rev Neurother. 2004;4(4):89–96.CrossRef
14.
Zurück zum Zitat Brem SS, Bierman PJ, Black P, Chamberlain MC, et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008;6(5):456–504.PubMed Brem SS, Bierman PJ, Black P, Chamberlain MC, et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008;6(5):456–504.PubMed
15.
Zurück zum Zitat Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–6.PubMedCrossRef Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–6.PubMedCrossRef
16.
Zurück zum Zitat Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5(10):1655–62.PubMed Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5(10):1655–62.PubMed
17.
Zurück zum Zitat Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561–9.PubMed Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561–9.PubMed
18.
Zurück zum Zitat Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394–402.PubMed Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394–402.PubMed
19.
Zurück zum Zitat Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.PubMed Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.PubMed
20.
Zurück zum Zitat Stapleton S, Blaney SM. New agents for intrathecal administration. Cancer Invest. 2006;24:528–34.PubMedCrossRef Stapleton S, Blaney SM. New agents for intrathecal administration. Cancer Invest. 2006;24:528–34.PubMedCrossRef
21.
Zurück zum Zitat Shapiro WR, Schmid M, Glantz M, Miller JJ. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol. 2006;24(June 6 Suppl):1528 abstract. Shapiro WR, Schmid M, Glantz M, Miller JJ. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol. 2006;24(June 6 Suppl):1528 abstract.
22.
Zurück zum Zitat Chamberlain MC. Alpha–interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675–80.PubMedCrossRef Chamberlain MC. Alpha–interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675–80.PubMedCrossRef
23.
Zurück zum Zitat Chamberlain MC, Wei-Tao DD, Groshen S. A phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer. 2006;31(9):2021–7.CrossRef Chamberlain MC, Wei-Tao DD, Groshen S. A phase 2 trial of intra-CSF etoposide in the treatment of neoplastic meningitis. Cancer. 2006;31(9):2021–7.CrossRef
24.
Zurück zum Zitat Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess HR, Yung WKA. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 2008;10(2):208–15.PubMedCrossRef Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess HR, Yung WKA. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 2008;10(2):208–15.PubMedCrossRef
25.
Zurück zum Zitat Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19(11):1978–80.PubMedCrossRef Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol. 2008;19(11):1978–80.PubMedCrossRef
26.
Zurück zum Zitat Glantz MJ, Cole BF, Recht L et al. High-Dose intravenous methotrexate for patients with nonelukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561–7.PubMed Glantz MJ, Cole BF, Recht L et al. High-Dose intravenous methotrexate for patients with nonelukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561–7.PubMed
27.
Zurück zum Zitat Boogerd W, Van den Bent MJ, Koehler PJ, Heimans JJ, Van der Sande JJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726–33.PubMedCrossRef Boogerd W, Van den Bent MJ, Koehler PJ, Heimans JJ, Van der Sande JJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer. 2004;40:2726–33.PubMedCrossRef
28.
Zurück zum Zitat Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115(4):730–6.PubMedCrossRef Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115(4):730–6.PubMedCrossRef
Metadaten
Titel
Carcinomatous meningitis
verfasst von
Marc C. Chamberlain, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0038-8

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe